Inovio press releases
WebNov 8, 2024 · PLYMOUTH MEETING, Pa., Nov. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious... WebApr 12, 2024 · INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA ®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com. Contacts Media: Jennie Willson (267) 429-8567 [email protected]
Inovio press releases
Did you know?
WebResearch & Development Center. 10480 Wateridge Circle San Diego, CA 92121 Phone: 858-597-6006 WebToday, INOVIO is poised to be the leader in the research and development of new and exciting DNA medicines to meet urgent health needs. We aspire to develop and deliver breakthrough DNA medicines and vaccines in disease states where effective cures have remained elusive. Innovation and a dynamic entrepreneurial spirit are at the core of who …
WebSep 17, 2024 · PLYMOUTH MEETING, Pennsylvania, Sept. 17, 2024 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that the company and its collaborator The Wistar Institute have... WebFeb 16, 2024 · PLYMOUTH MEETING, Pa., Feb. 16, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
WebApr 12, 2024 · INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA ®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com. Contacts Media: Jennie Willson (267) 429-8567 [email protected] WebINOVIO to Report Fourth Quarter and Year-End 2024 Financial Results on March 1, 2024. INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV … Analyst Coverage - Inovio Pharmaceuticals, Inc. - INVESTORS & MEDIA INOVIO is leveraging its optimized plasmid design and delivery technology to … SEC Filings - Inovio Pharmaceuticals, Inc. - INVESTORS & MEDIA Investors & Media - Inovio Pharmaceuticals, Inc. - INVESTORS & MEDIA Research & Development Center. 10480 Wateridge Circle San Diego, CA 92121 … Disease Program Study Phase Summary; DiseaseBRCA1/2 Mutation Carriers (More … INOVIO is powering DNA medicines through collaborations with industry, academia, …
WebMar 29, 2024 · INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis. …
WebLatest Inovio News April 3, 2024 INOVIO Reports Inducement Grant Under Inducement Plan (read more) March 3, 2024 INOVIO to Present at the Oppenheimer 33rd Annual Healthcare … thales cwiWebInovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2024 Earnings Call Transcript March 1, 2024 Operator: Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2024 Financial... synopsys office locationsWebDec 23, 2004 · PLYMOUTH MEETING, Pa., April 12, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO ), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people... thales damoclesWebApr 12, 2024 · Immunological data from recently completed Phase 1b trial will be presented on April 16th PLYMOUTH MEETING, Pa., April 12, 2024 /PRNewswire/ -- INOVIO … thales crotaleWebApr 2, 2024 · CHICAGO – Blue Cross and Blue Shield of Illinois (BCBSIL) announced today it is waiving member cost-sharing, including deductibles, copayments and coinsurance, … thales ctoWebThe INO_News flair exists to be used when there’s actual Inovio-related news (such as PR, clinical trial updates, vaccine purchase orders etc). Your post may be removed if deemed unrelated. Please see the flair guide if you are unsure about your use of flair. I am a bot, and this action was performed automatically. thales czechWebwww.inovio.com synopsys mountain view office